Digital Health Global

02/04/2024

The Finnish Ministry of Social Affairs and Health is proud to present a special program at the Radical Health Festival Helsinki 2024, showcasing Finland’s unique expertise in digital health to an international audience

Hosted by the Finnish Ministry of Social Affairs and Health, Radical Health Festival Helsinki 2024 features an exclusive full-day program of site visits and high-level conversations for international ministerial delegations and selected participants.
The curated program by the ministry provides an excellent view of Finland’s leading landscape and offers a unique opportunity to find inspiration and forge potential partnerships.

More at https://www.digitalhealthglobal.com/radical-health-festival-the-finnish-ministry-of-social-affairs-and-health-will-present-a-special-program/

Digital Health Global is the leading global channel for news, insight and analysis on the latest dev

28/03/2024

From all of us at , a wish for a wonderful Easter filled with love, laughter, and health!

As we gather with loved ones to celebrate this joyous occasion, let's also remember to prioritize our health and well-being.
Here are some digital health tips to keep in mind during these days:

𝐒𝐭𝐚𝐲 𝐀𝐜𝐭𝐢𝐯𝐞: Whether it's an Easter egg hunt or a leisurely stroll in the park, staying active can boost your mood and energy levels.

𝐌𝐢𝐧𝐝𝐟𝐮𝐥 𝐄𝐚𝐭𝐢𝐧𝐠: Indulge in Easter treats mindfully. Enjoy your favorite treats in moderation and balance them with nutritious foods.

𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐃𝐞𝐭𝐨𝐱: Consider taking breaks from screens to fully immerse yourself in the present moment and enjoy quality time with loved ones.

14/03/2024

📣 Explore 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 framework, providing a guide for employing innovative strategies 𝒊𝒏 𝒍𝒊𝒇𝒆 𝒔𝒄𝒊𝒆𝒏𝒄𝒆𝒔.

📆 Join the team at Healthware Group, an EVERSANA INTOUCH Agency, on Monday, March 25th at 15:00 GMT / 16:00 CET / 10:00 EST as they reflect on what ‘Innovation as Strategy’ means to them, offering their perspectives along with practical advice and real-world examples.

🔎 𝐑𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐢𝐬 𝐟𝐫𝐞𝐞 𝐛𝐮𝐭 𝐦𝐚𝐧𝐝𝐚𝐭𝐨𝐫𝐲 𝐭𝐨 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐰𝐞𝐛𝐢𝐧𝐚𝐫:

Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences. These expert panellists will reflect on what ‘Innovation as Strategy’ means to them, offering their perspectives, along with practical advice and real-world examples.

12/03/2024

What is the impact of AI models on clinician diagnostic accuracy? A recent study in the JAMA, Journal of the American Medical Association, titled "𝐌𝐞𝐚𝐬𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐀𝐈 𝐢𝐧 𝐭𝐡𝐞 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬 𝐨𝐟 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐢𝐳𝐞𝐝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬", sheds light on the matter and reveals intriguing findings. 🔎

📈 Clinicians experienced a notable 4.4% increase in diagnostic accuracy when powered by standard AI model predictions...

📉 ...but they also faced an 11.3% drop in accuracy when encountering systematically biased AI predictions.

While is surely enhancing , addressing systematic biases is crucial to maintain patient care standards.

👉 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐟𝐨𝐫𝐰𝐚𝐫𝐝 𝐭𝐨 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐫𝐞𝐬𝐮𝐥𝐭𝐬? Read more in the article by Sara Scarpinati, Marketing & Communications Manager at EVERSANA:

In a groundbreaking study published in the Journal of the American Medical Association (JAMA), researchers shed light on the impact of artificial

11/03/2024

In today's healthcare landscape, 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 ( ) emerge as a transformative force. Yet, navigating from concept to clinical implementation poses intricate challenges. 🔎

📑 A recent study titled “𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐟𝐫𝐨𝐦 𝐁𝐞𝐧𝐜𝐡 𝐭𝐨 𝐁𝐞𝐝𝐬𝐢𝐝𝐞” delves into the world of DTx, offering insights and integration strategies. Through ongoing dialogue, DTx promise to revolutionize , advancing personalized medicine and patient-centered care.

📈 As demand grows, concerted efforts are needed to navigate regulatory complexities and harness DTx’s transformative power in shaping the future of healthcare. Discover more in the article by Sara Scarpinati, Marketing & Communications Manager at EVERSANA:

In the rapidly evolving landscape of healthcare, digital therapeutics (DTx) emerge as a transformative force, offering innovative solutions to improve

06/03/2024

𝐓𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐔𝐧𝐢𝐨𝐧’𝐬 𝐀𝐈 𝐀𝐜𝐭 𝐢𝐬 𝐬𝐞𝐭 𝐭𝐨 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐀𝐈 𝐢𝐬 𝐮𝐭𝐢𝐥𝐢𝐳𝐞𝐝 𝐚𝐧𝐝 𝐠𝐨𝐯𝐞𝐫𝐧𝐞𝐝 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐞 𝐄𝐔. 🤖

⚖ This significant regulatory framework will ensure safety and transparency in the use of , protecting people against potential abuses. Expected to be fully activated by 2026, the Act will present an opportunity for leadership in responsible AI development.

Here's a breakdown of its key aspects and the impacts on organizations:
🚫 Bans on systems threatening fundamental rights.
🔍 Classification of AI systems based on risk levels.
🎭 Emphasis on , , and non-discrimination.
🔒 Strict regulations for high-risk AI systems.

As the EU AI Act takes center stage, are we witnessing the birth of a new era in AI governance? Read more in the article by Lino Fioravante Mari, Head of Technology at Healthware Group:

The European Union's AI Act is a significant regulatory framework that aims to govern the use of artificial intelligence (AI) within the EU.

04/03/2024

A recent UK project explored the integration of the Garmin Venu 2 into medical processes: how does it work? ⌚

👨‍⚕️ Dr. Joseph Newman's research has demonstrated how these devices can revolutionize tests like the 𝐒𝐢𝐱 𝐌𝐢𝐧𝐮𝐭𝐞 𝐖𝐚𝐥𝐤 𝐓𝐞𝐬𝐭, improving patient care and reducing hospital visits for cardiovascular conditions.

🏡 This innovation could potentially open possibilities for at-home monitoring, aligning with patients' daily lives. For more information, read our article: https://www.digitalhealthglobal.com/revolutionizing-clinical-diagnostics-with-smartwatch-innovation/

Recently, the Food and Drug Administration (FDA) issued a press release warning against the use of wearable devices in measuring blood glucose levels.

01/03/2024

𝐖𝐡𝐚𝐭 𝐡𝐚𝐩𝐩𝐞𝐧𝐞𝐝 𝐭𝐡𝐢𝐬 𝐩𝐚𝐬𝐭 𝐰𝐞𝐞𝐤 𝐢𝐧 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝 𝐨𝐟 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡? From immersive training programs to innovative , we have selected some of the most important events, brought to you thanks to our editorial partnership with Business Wire. Join us as we delve into the latest advancements and strategic alliances in digital health. 💡

🤝 aNUma has partnered with UC Berkeley Center for the Science of Psychedelics to integrate their Experience Platform with the Psychedelic Facilitation Certificate Program. Through immersive experiences, their goal is to enhance trainee facilitators' skills in presence, empathy, and . https://www.digitalhealthglobal.com/anuma-contracted-by-university-of-california-at-berkeleys-center-for-the-science-of-psychedelics-certificate-program-to-explore-psychedelic-facilitation-training-with-innovative-digital-platf/

💊 Walgreens has become the first community pharmacy to accept Medicare Advantage supplemental benefits online. This move enhances accessibility for customers, complementing existing in-store options and furthering Walgreens' commitment to accessible care and digital health solutions. https://www.digitalhealthglobal.com/walgreens-first-community-pharmacy-to-accept-a-broad-array-of-medicare-advantage-supplemental-benefits-online-and-in-app/

👥 Curbside Health has partnered with OSF HealthCare to implement its clinical effectiveness platform, promoting standardized patient care and clinical excellence. OSF HealthCare will utilize Curbside's decision support software to enhance healthcare delivery across its network. https://www.digitalhealthglobal.com/osf-healthcare-implements-curbside-health-to-advance-clinical-guidelines-support-patient-care-excellence/

📲 Validic has expanded its healthcare IoT platform by integrating Smart Meter, LLC's cellular-enabled monitoring devices. This collaboration aims to provide a reliable and secure delivery of patient-generated data to Validic clients without the need for patient pairing or connecting to Wi-Fi. https://www.digitalhealthglobal.com/validic-integrates-with-smart-meter-cellular-enabled-connected-health-devices/

29/02/2024

The 𝐁𝐚𝐫𝐫𝐞𝐭𝐭’𝐬 𝐎𝐞𝐬𝐨𝐩𝐡𝐚𝐠𝐮𝐬 𝐈𝐦𝐚𝐠𝐢𝐧𝐠 𝐟𝐨𝐫 𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 (𝐁𝐎𝐍𝐒-𝐀𝐈) 𝐜𝐨𝐧𝐬𝐨𝐫𝐭𝐢𝐮𝐦 has introduced a groundbreaking 𝐂𝐨𝐦𝐩𝐮𝐭𝐞𝐫-𝐀𝐢𝐝𝐞𝐝 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 (𝐂𝐀𝐃𝐞) system to improve the efficiency of identifying neoplastic lesions.

📊 The results of the study, published in The Lancet Digital Health, are impressive: CADe showcases impressive levels of sensitivity and moderate specificity in real-world scenarios, surpassing the performance of general endoscopists.

👉 CADe integration promises to advance early neoplasia detection to new heights while providing invaluable assistance to medical professionals. Dive deeper into the details in our article: https://www.digitalhealthglobal.com/detecting-neoplasia-in-barretts-oesophagus-with-cade/

29/02/2024

𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐭𝐡𝐚𝐭 𝐫𝐚𝐫𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐢𝐦𝐩𝐚𝐜𝐭 𝐚𝐧 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝟑𝟎𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐩𝐞𝐨𝐩𝐥𝐞 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲, 𝐰𝐢𝐭𝐡 𝐚𝐫𝐨𝐮𝐧𝐝 𝐨𝐧𝐞 𝐢𝐧 𝐟𝐢𝐯𝐞 𝐜𝐚𝐧𝐜𝐞𝐫𝐬 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐞𝐝 𝐫𝐚𝐫𝐞? 𝐘𝐞𝐭, 𝐦𝐚𝐧𝐲 𝐟𝐚𝐜𝐞 𝐩𝐨𝐨𝐫 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 𝐨𝐟 𝐜𝐚𝐫𝐞 𝐝𝐮𝐞 𝐭𝐨 𝐥𝐢𝐦𝐢𝐭𝐞𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐩𝐭𝐢𝐨𝐧𝐬. 🌍

🏥 During 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐚𝐲, we want to focus attention on clinical trials as a source of success in improving more and more ways of dealing with these diseases. New technologies like synthetic control arms ( ) are revolutionizing the landscape. By leveraging historical data, SCAs offer a promising solution to accelerate trials, reduce placebo usage, and bring treatments to patients faster.

💡 With decentralization tools, we're overcoming challenges and witnessing a paradigm shift in research. These innovations could also optimize research investment returns. How? Discover more in this article by Ruthie Davi and Elizabeth Lamont, MD, MS for pharmaphorum:

Rare Disease Day is an opportunity to highlight the importance of enhancing clinical trial success in rare diseases for the benefit of patients.

28/02/2024

𝐇𝐨𝐰 𝐦𝐮𝐜𝐡 𝐝𝐨 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐰𝐨𝐦𝐞𝐧'𝐬 𝐡𝐞𝐚𝐥𝐭𝐡? ♀

🙋‍♀️ In this era of rapid medical changes and innovations, it's more important than ever to advocate for comprehensive and inclusive healthcare policies and practices that prioritize the diverse needs of .

💡 Join us in a series curated by Anastasiya Markvarde, Sr. Innovation Manager & Business Development at Healthware Group, where she delves into groundbreaking research, innovations, and initiatives empowering women to take control of their .

👉 Explore with us as we uncover insights into autoimmune diseases, share promising outcomes from the first non-hormonal treatment for , and gain valuable insights into chronic diseases and . 𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝘁𝗵𝗲 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻:

Time to share my women’s health updates from February 2024: research breakthroughs, clinical trial findings, endometriosis deep dive, and more. A Stanford

27/02/2024

Big news in the world of ! Akili just announced that its Japanese partner, Shionogi & Co., Ltd, has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare in Japan.
This marks a significant step forward for the Japanese version of Akili’s AKL-T01, known as ® in the United States. https://www.digitalhealthglobal.com/akili-announces-positive-results-from-shionogis-phase-3-clinical-trial-of-localized-version-of-akilis-endeavorrx-for-pediatric-adhd-patients-in-japan/

EndeavorRx® was previously authorized by the U.S. Food and Drug Administration ( FDA) as the world’s first for improving attentional functioning in pediatric patients aged 8 to 17. Now, with the submission for marketing approval in Japan, the localized SDT-001 could potentially offer an effective and safe treatment option for pediatric patients with ADHD in Japan.

Dr. Scott Kollins, Chief Medical Officer at Akili, emphasized the importance of the latest Japanese clinical trial, stating that it not only validates the efficacy and safety of EndeavorRx but also brings them a step closer to making the product available in Japan. If approved, SDT-001 could fill a gap in pharmaceutical therapies for pediatric ADHD patients in the country.

The submission is based on the positive results of the Phase 3 clinical trial conducted by SHIONOGI in Japan. In this trial, SDT-001 demonstrated statistically significant improvements in ADHD symptoms compared to the control group. Notably, no safety concerns or serious adverse events related to SDT-001 were observed. The sustained symptom improvements after two cycles of SDT-001 use are particularly promising.

This development reinforces the potential global impact of digital therapeutics in improving healthcare outcomes, especially in the realm of pediatric ADHD treatment.

Japanese Product Now Under Review for Nationwide Marketing ApprovalBOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital ...